Syncom Formulations (India) Analysis

dividend

Pros

Cons

• Unable to calculate sustainability of dividends as Syncom Formulations (India) has not reported any payouts.
• Unable to evaluate Syncom Formulations (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Syncom Formulations (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Syncom Formulations (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
• Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (98.3%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 9.3x debt.
• Syncom Formulations (India)'s cash and other short term assets cover its long term commitments.
• Syncom Formulations (India) earns more interest than it pays, coverage of interest payments is not a concern.
• Syncom Formulations (India)'s level of debt (6.3%) compared to net worth is satisfactory (less than 40%).

Cons

• The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
• High level of physical assets or inventory.

management

Pros

• The average tenure for the Syncom Formulations (India) board of directors is over 10 years, this suggests they are a seasoned and experienced board.
• Vijay's remuneration is lower than average for companies of similar size in India.
• Vijay's compensation has been consistent with company performance over the past year, both up more than 20%.
• More shares have been bought than sold by Syncom Formulations (India) individual insiders in the past 3 months.
• The average tenure for the Syncom Formulations (India) management team is over 5 years, this suggests they are a seasoned and experienced team.

Cons

misc

Pros

Cons

• Syncom Formulations (India) is not covered by any analysts.
• Syncom Formulations (India) has significant price volatility in the past 3 months.

past

Pros

• Syncom Formulations (India)'s 1-year earnings growth exceeds its 5-year average (22% vs 5.1%)
• Syncom Formulations (India)'s year on year earnings growth rate has been positive over the past 5 years.

Cons

• Syncom Formulations (India) used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Syncom Formulations (India)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
• Syncom Formulations (India) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• Syncom Formulations (India)'s earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (22% vs 22.7%).

value

Pros

• Syncom Formulations (India) is good value based on assets compared to the IN Pharmaceuticals industry average.
• Syncom Formulations (India) is good value based on earnings compared to the IN Pharmaceuticals industry average.
• Syncom Formulations (India) is good value based on earnings compared to the India market.
• 524470 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• 524470 outperformed the Market in India which returned -14.5% over the past year.
• BSE:524470 is up 54.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:524470 is up 54.9% outperforming the market in India which returned 8% over the past month.

Cons

• Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a substantial discount (< 40%).